



OFFICE OF THE ATTORNEY GENERAL

Catherine Cortez Masto, *Attorney General*

555 E. Washington Avenue, Suite 3900
Las Vegas, Nevada 89101
Telephone - (702) 486-3420
Fax - (702) 486-3283
Web - <http://ag.state.nv.us>

FOR IMMEDIATE RELEASE
DATE: November 15, 2012

CONTACT: Jennifer López
jlopez@ag.nv.gov / 702-486-3782

ATTORNEY GENERAL MASTO AND 37 ATTORNEYS GENERAL NATIONWIDE REACH A \$90 MILLION SETTLEMENT WITH GLAXOSMITHKLINE CONCERNING AVANDIA

Las Vegas, NV – Nevada Attorney General Catherine Cortez Masto announced today that she and 37 other Attorneys General reached a \$90 million consent judgment with GlaxoSmithKline LLC to resolve allegations that GlaxoSmithKline unlawfully promoted its diabetes drug, Avandia®.

The Attorneys General allege that GlaxoSmithKline engaged in unfair and deceptive practices by misrepresenting Avandia's cardiovascular risks and safety profile.

"These enforcement provisions are important to protect Nevadans and others across the country," said Masto. "I am pleased to join this multistate agreement to ensure that Nevadans are not misled by this company's deceptive marketing practices."

As part of the consent judgment, GlaxoSmithKline ("GSK") agreed to reform how it markets and promotes diabetes drugs. Under the consent judgment, GSK may not:

- Make any false, misleading, or deceptive claims about any diabetes drug;
- Make comparative safety claims not supported by substantial evidence or substantial clinical experience;
- Present favorable information previously thought of as valid but rendered invalid by contrary and more credible recent information;
- Promote investigational drugs; or
- Misuse statistics or otherwise misrepresent the nature, applicability, or significance of clinical trials.

The consent judgment also has the following terms that are effective for at least eight years:

- GSK must post summaries of all GSK-sponsored observational studies or meta-analyses conducted by GSK that are designed to inform the effective, safe, and/or appropriate use of its diabetes drugs;

- GSK shall post summaries of GSK-sponsored clinical trials of diabetes products within eight months of the primary completion date;
- GSK shall register and post all GSK-sponsored clinical trials as required by federal law; and
- GSK shall comply with the International Committee of Medical Journal Editors Uniform Requirements for Manuscripts submitted to Biomedical Journals.

Nevada will receive \$1,521,178 as its share of the settlement. Chief Multistate Counsel JoAnn Gibbs represented Nevada in this matter.

The investigation was led by the Attorneys General of Oregon and Illinois with an Executive Committee consisting of the Attorneys General of Arizona, Florida, Maryland, Pennsylvania, Tennessee, and Texas. Also participating in the settlement are Alabama, Alaska, Arkansas, California, Colorado, Connecticut, Delaware, the District of Columbia, Hawaii, Idaho, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Jersey, North Carolina, North Dakota, Ohio, Oklahoma, Rhode Island, South Dakota, Vermont, Washington, and Wisconsin.

###